CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + tram...
Phase 3
Seattle, Washington, United States and 31 other locations
efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...
Phase 3
Seattle, Washington, United States and 49 other locations
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...
Phase 2
Seattle, Washington, United States and 56 other locations
The purpose of this study is to assess the patient's preference for nivolumab subcutaneous (SC) or nivolumab + relatlimab fixed-dose combination (FDC...
Phase 2
Seattle, Washington, United States and 36 other locations
artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma...
Phase 1
Seattle, Washington, United States and 9 other locations
with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC)....
Phase 1
Seattle, Washington, United States and 17 other locations
The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma....
Phase 3
Seattle, Washington, United States and 135 other locations
of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma...
Phase 3
Seattle, Washington, United States and 82 other locations
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to...
Phase 1
Seattle, Washington, United States and 21 other locations
(PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma...
Phase 2
Seattle, Washington, United States and 56 other locations
Clinical trials
Research sites
Resources
Legal